Thiamine (Vitamin B1)
Of 9,912 on-market thiamine (vitamin b1) products in the January 2026 DSLD dump, the median declared dose is 3 mg, and 74.1% list Thiamine Hydrochloride (Thiamine HCl) as the primary form.
Form share
Of 7,542 products with an identifiable primary form, here is the share held by each form of Thiamine (Vitamin B1) on the market today.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Thiamine Hydrochloride (Thiamine HCl) | Tier 1 | 5,586 | 74.1% |
| Thiamine Mononitrate | Tier 1 | 1,956 | 25.9% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 7,379 products with a disclosed amount, against the RDA of 1.2.
- 99.0% of products fall below the fairy-dust threshold (120 mg, 20% of the studied low dose).
- 0.4% of products don't disclose an amount because Thiamine (Vitamin B1) is declared inside a proprietary blend.
By dosage form
By target group
Top brands
Forms explained
Elemental fraction: 78.7% (thiamine cation MW 265.36 / thiamine HCl MW 337.26 (both confirmed PubChem formulas))
Regulatory/industry assessments treat HCl and mononitrate as bioequivalent -- both fully hydrolyze to the same thiamine cation and convert to the active cofactor thiamine pyrophosphate; HCl's higher water solubility is used in liquid/injectable products.
Source: EFSA feed-additive dossier assessments, PMC12035548/PMC11979709
Elemental fraction: 81.1% (thiamine cation MW 265.36 / thiamine mononitrate MW 327.36 (confirmed PubChem formula))
Same rationale as HCl -- bioequivalent; preferred for fortification for stability (non-hygroscopic), not superior bioavailability.
Source: EFSA feed-additive dossier assessments, PMC12035548/PMC11979709
Early trials suggested neuropathy-symptom benefit, but longer/larger trials (BOND 12-month T2D, 24-month T1D) found no significant benefit on nerve function despite good tolerability -- superior-bioavailability claims are not settled.
Source: BENDIP trial (Stracke et al.); BOND study 2025; 24-month T1D RCT, Diabetes Care 2012;35(5):1095
Reference values
- RDA (adult): 1.2 mg — 1.2mg (men); 1.1mg (women), ages 19+
- Tolerable Upper Intake Level (adult): not established — Not established -- data on adverse effects insufficient to set a UL; no observed toxicity from oral thiamine even at high doses
- Studied clinical dose range: 600–1800 mg
- Bager P et al. 2021, Aliment Pharmacol Ther 53(1):79-86, PMID 33210299 -- crossover RCT (n=40), high-dose oral thiamine HCl significantly reduced fatigue scores vs placebo (mean reduction 4.5 points vs +0.75 for placebo, p=0.0003) in quiescent IBD patients.
- Note: No DFE-style equivalency system applies to thiamine. The 600-1800mg studied range is a research dose, not a label safety limit -- no UL is established.